Scancell Share Discussion Threads

[inanaco] 18/2/2019 10:57

Bermuda . CD4 can differentiate

CD4 +T cells are crucial in achieving a regulated effective immune response to pathogens. Naive CD4 +T cells are activated after interaction with antigen-MHC complex and differentiate into specific subtypes depending mainly on the cytokine milieu of the microenvironment.


want of a better word ... Shape changers ...

so if the signal is to Suppress .......... They can !

[bermudashorts] 18/2/2019 10:46

Inanaco,

I thought ImmunoBody generated primarily CD8 response and Moditope CD4 - will check but am sure that's how Scancell have presented the two vaccines in the past.

[inanaco] 18/2/2019 10:22

Tf you have to appreciate that a Immunobody CD4+T cell is very important as not only its activity is to promote inflammation ...But when subject to the pd-1 ligand it actually promotes T cell regulation .. causing the immune system to go into reverse !!


These results suggest that the PD-1/PD-L1 pathway plays a role in Treg induction and is associated with impaired adaptive immunity. In the tumor microenvironment, PD-1 expressed on Tregs accelerates CD4+ T cells differentiating into Foxp3+ Tregs under the circumstances of CD3 and TGF-β. Foxp3 is a critical transcription factor of Tregs, which suppress Th1 responses [94]. Foxp3+ Tregs is a highly immunosuppressive subset of CD4+ T cells that is critical in suppressing proliferation and cytokine production of other T cells, inhibiting tumor-specific immune responses and maintaining peripheral immune tolerance in cancer patients [114]. Meanwhile, Treg cells express constitutive high levels of PD-1, which enhance Treg functional response or proliferation and inhibit T cells responses

this is another area that Can be blocked by Keytruda ...

which is why every bit of data i find tells me .. Keytruda Plus SCIB1 = Synergy

[torquayfan] 18/2/2019 10:01

Thanks Guys.

[inanaco] 18/2/2019 09:49

scib2 targets

CD4+ T cell epitopes NY-ESO-1 87–111 and 119–143

SCIB1 targets Gp100

[inanaco] 18/2/2019 09:18

He is understanding the importance of all CD4 + ... Immunobody also targets CD4 +
Helper T cells to become effector cells .. its this priming again that is so important in the way the T cell performs against cancer

by the way they have another form of self destruction as the immune response subsides, loss of the antigen and the cytokine results in them self destructing ....

the Kidneys and the Liver are not involved ...

[bermudashorts] 18/2/2019 09:02

TF,

It's this sentence:-

'“I think there are ways around that, involving the development of CD4-TARGETED AGENTS, particularly using VACCINES''

Moditope = CD4

[torquayfan] 18/2/2019 08:28

I remember seeing BB comments that Modi will function without CI ?
What are you getting at ? Thanks.

[bermudashorts] 18/2/2019 08:15

TF - yes it is and it was a genuine and important question.

[torquayfan] 18/2/2019 08:11

Bermuda - I'm just glad to see THE man enthusing about vaccines.
I thought it was a very interesting link.

[bermudashorts] 18/2/2019 07:44

TF

Thanks for that - so are we now suggesting that Moditope will also be a combination therapy?

[10acious] 17/2/2019 16:37

Come on now, don't be shy, say what you mean!

[inanaco] 17/2/2019 15:43

Don't forget the SCIB1 mouse model is proven ... LOL

[bermudashorts] 17/2/2019 15:21

10acious

Of course the field is so crowded because the rewards are so high. In the interest of balance this is from Scancell:-

'results demonstrate that it might be possible to rescue a poor vaccine and/or a non-responsive anti-PD-1 tumor by using a combination but then the survival is still very low. In contrast, our vaccine alone gives good survival and anti-PD-1 alone shows therapeutic efficacy in 50% of the animals (similar to results in melanoma patients) but the combination gives an overall survival of 80%.'

[10acious] 17/2/2019 14:10

Thank you for that, very much an eye opener for me.What a crowded field,that has it seems,developed into nothing more than a dash for the cash. Easy now to see why progress for Scancell appears to be so slow.With the competition so vast the resources so relatively limited and failure rates as high as they are I'm happy to leave this in the... small speculative punt...bottom draw!As David Berman, who runs immuno-oncology at AstraZeneca, puts it bluntly: "Everything works in mice." And while animal models have improved in recent years, "they aren't as helpful as they were in other types of therapy-and even there, it's questionable how much predictiveness they have," adds Joanne Lager, who leads oncology development at Sanofi.Liked that bit of reality.

[kreature] 17/2/2019 12:00

Why is the market cap a whopping 24m?

[bermudashorts] 17/2/2019 11:38

10acious thanks for that - below is link to an article posted a few months ago now. It's the best article on combination studies that I've read - not too detailed or technical and gives a good basic outline of the issues. It's a long article but would strongly recommend that any holders here have a read.

Re. your comment on patient nos. the article only includes figures up to 2017 but during the last 18 months there has been an explosion in the number of combination studies - depending on what article you read there are now between 1500 and 2500 trials. According to the Cancer Research Institute the figure is 2250 which involves the need to recruit over 380,000 patients. In some cancers there simply aren't enough patients to fill the trials.

The fact that Scancell have signed up major cancer centres in the US for the SCIB1 trial should very much help with recruitment for SCIB1 (assuming there's no change from previous announcements). When it comes to SCIB2, CRUK have a network of dedicated clinical trial centres.

[terror] 17/2/2019 09:27

Scancell have attended more meetings and presentations than Donald Trump.

It makes no difference to a positive outlook, indeed, it has a negative impact on the share price because they continue to burn money without income.

They have lost their way

[10acious] 17/2/2019 08:28

Immunotherapies could change kidney cancer care, studies suggesthttps://www.cnn.com/2019/02/16/health/kidney-cancer-immunotherapies-combination-drug-study/index.htmlNot directly related but I found the numbers involved in the trial interesting....

[bermudashorts] 16/2/2019 13:14

Dr - yes exactly, it's an investment conference so assume CH will be attending. Let's hope he needs to update his pitch with some progress on both platforms.

[bermudashorts] 16/2/2019 12:00

Looks like Scancell are attending Biotrinity in London in April.

[torquayfan] 16/2/2019 02:12

Gazza. Thanks for the reply. Nice weekend to you.